Incidence, Clinical Features, and Outcomes of Late‐Onset Neutropenia From Rituximab for Autoimmune Disease

Review of 738 patients given rituximab (various indications) found a cumulative incidence of late‐onset neutropenia of 6.6% after 1 year. The incidence decreased thereafter, from 7.2 cases per 100 person years in the first year to 1.5 cases thereafter.

Source:

Arthritis & Rheumatology